Position in RNA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$303,605
New position
Shares Held
22,708
first reported quarter
Ownership
0.133%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0%
Shared 100%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Point72 Asset Management, L.P. holds $2,393,450,612 across 188 Biotechnology names. RNA ranks #153 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APLS |
Apellis Pharmaceuticals, Inc.
|
4,183,918 | $168,319,021 | |
| 2 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
225,510 | $118,047,719 | |
| 3 | CLDX |
Celldex Therapeutics, Inc.
|
3,229,939 | $102,453,665 | |
| 4 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
846,801 | $73,646,282 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
424,750 | $71,791,245 | |
| 6 | ABVX |
Abivax S.A.
|
637,736 | $71,011,903 | |
| 7 | LEGN |
Legend Biotech Corp
|
3,886,017 | $70,298,047 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
358,634 | $67,799,757 |
All Filings in RNA
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $303,605 | 22,708 | Shares | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||